In 1999, tanespimycin entered clinic as the first HSP90 inhibitor, and showed good therapeutic effect in various cancers either in single dose or in combinations, including melanoma,393 ERBB2‐positive metastatic breast cancer,394 refractory MM,395 and so on. Here, ERBB2 is linked to cancer.